Enter multiple symbols separated by commas

Sanofi-Aventis' Shares Dive After FDA Rejects Weight-Loss Drug

Investors wiped some 6 billion euros ($7.97 billion) off the market value of French pharmaceutical company Sanofi-Aventis Thursday after U.S. federal health advisers rejected its Accomplia weight-loss drug.

The Food and Drug administration's advisory panel rejected the drug, also known as rimonabant and Ziumlti, after hearing testimony that it increases the risk of suicidal thoughts, even in patients with no history of depression.

Shares fell 6.8% to 62.67 euros ($83.27) at the open of trade Thursday.

Sanofi-Aventis failed to show the drug is safe, the FDA panel said Wednesday. The unanimous vote by the 14-member panel made it unlikely the FDA will approve the drug. The agency usually follows its panel's advice, but it is not required to do so.

In a statement, Sanofi said it would "continue to work closely with the FDA to address the committee's recommendations."

Goldman Sachs puts Sanofi-Aventis' rating, earnings estimates and price target under review after the FDA panel announcement.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • Bull trades for dog days

    John Stoltzfus, Oppenheimer chief market strategist, expects 10 percent upside by year-end in the S&P 500.

  • Best & worst stocks for August

    CNBC's Dominic Chu uses data from Kensho to find out the best and worst performers in the Dow during August historically.

  • When will oil turn?

    Baker Hughes announced an increase in the U.S. oil rig count. Steven Kopits, Princeton Energy Advisors, shares his bull case for oil.